BDRX · Biodexa Pharmaceuticals Plc

NasdaqHealthcareBiotechnology

Biodexa Pharmaceuticals Plc Is A Clinical-Stage Biopharmaceutical Company Focused On Developing A Pipeline Of Products To Treat Diseases That Have Unmet Medical Needs. These Include Familial Adenomatous Polyposis (Fap), Non-Muscle Invasive Bladder Cancer (Nmibc), Type 1 Diabetes (T1d), And Rare Or Orphan Brain Cancers.

HealthcareNasdaqGBUltra Low Float

$0.66

+70.0% latest move

Price & move as of the most recent catalyst (Oct 13) — not a live quote.

FLOAT

605.9K

FREE FLOAT %

14%

SHARES O/S

4.2M

MARKET CAP

$394,338.09

EXCHANGE

Nasdaq

COUNTRY

BDRX Catalyst History

Regulatory and ClinicalTrial Enrollment CompleteOct 13, 2026 · 8:30am ET

BDRXBiodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc Enrolls 100 Patients in Serenta Phase 3 Trial

The milestone marks significant progress in the trial for FAP treatment.

Be early on the next BDRX spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

BDRX · Biodexa Pharmaceuticals Plc

BDRX Catalyst History

Biodexa Pharmaceuticals Plc Enrolls 100 Patients in Serenta Phase 3 Trial

Biodexa Pharmaceuticals Plc Enrolls 100 Patients in Serenta Phase 3 Trial

Biodexa Pharmaceuticals Plc Announces Major Milestone for Serenta Phase 3 Trial

Biodexa Pharmaceuticals Plc Announces Major Milestone for Serenta Phase 3 Trial

Biodexa Pharmaceuticals Plc Reports Stock Surge

Biodexa Pharmaceuticals Plc Reports Stock Surge